Core Viewpoint - The content emphasizes the importance of conducting personal due diligence and consulting competent advisors before making any financial decisions, particularly in the context of investments and trading activities [1]. Group 1 - The website provides general news, personal analysis, and third-party content intended for educational and research purposes [1]. - It explicitly states that the information should not be interpreted as recommendations or advice for any financial actions [1]. - The content is not tailored to individual financial situations or needs, highlighting the necessity for users to apply their own discretion [1]. Group 2 - The website includes information about complex financial instruments such as cryptocurrencies and contracts for difference (CFDs), which carry a high risk of losing money [1]. - Users are encouraged to perform their own research and understand the risks involved before investing in any financial instruments [1].

Company Overview - United Therapeutics Corporation is based in Silver Spring, MD and markets four medicines in the United States for treating pulmonary arterial hypertension (PAH): Remodulin, Orenitram, Tyvaso, and Adcirca [7] Earnings Estimates - Seven analysts have revised their earnings estimates upwards for fiscal 2024, with the Zacks Consensus Estimate increasing by $0.85 to $24.62 per share [8] - United Therapeutics boasts an average earnings surprise of 12.4% [8] Investment Ratings - United Therapeutics has a Zacks Rank of 3 (Hold) and a Value Style Score of B, indicating attractive valuation metrics such as a forward P/E ratio of 11.23 [20] - The company also has a VGM Score of A, suggesting strong overall performance potential [20][21] Investment Strategy - To maximize investment returns, it is recommended to consider stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B [18] - Stocks with a 3 (Hold) rank should also have Style Scores of A or B to ensure upside potential [18]

Group 1: Zacks Style Scores Overview - Zacks Style Scores are complementary indicators that rate stocks based on value, growth, and momentum characteristics, helping investors identify stocks with the best chances of outperforming the market over the next 30 days [2][3] - Each stock is assigned a rating from A to F, with A indicating the highest potential for outperformance [3] - The Style Scores are categorized into four types: Value Score, Growth Score, Momentum Score, and VGM Score, which combines all three styles [3][4][5] Group 2: Value Score - The Value Score identifies attractive and discounted stocks using ratios like P/E, PEG, Price/Sales, and Price/Cash Flow [3] Group 3: Growth Score - The Growth Score focuses on a company's financial strength and future outlook, analyzing projected and historical earnings, sales, and cash flow [4] Group 4: Momentum Score - The Momentum Score helps investors capitalize on price trends, using factors like one-week price change and monthly earnings estimate changes [4] Group 5: VGM Score - The VGM Score combines Value, Growth, and Momentum Scores to provide a comprehensive indicator for stock selection [5] Group 6: Zacks Rank - The Zacks Rank is a proprietary stock-rating model based on earnings estimate revisions, helping investors build successful portfolios [6] - Stocks rated 1 (Strong Buy) have produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [7] Group 7: Stock to Watch - United Therapeutics (UTHR) - United Therapeutics Corporation markets four medicines for pulmonary arterial hypertension, including Remodulin, Orenitram, Tyvaso, and Adcirca [10] - UTHR is currently rated 3 (Hold) on the Zacks Rank, with a VGM Score of A and a Momentum Style Score of A, having increased 4.9% over the past four weeks [11] - The Zacks Consensus Estimate for UTHR's fiscal 2024 earnings has risen by $1.16 to $24.62 per share, with an average earnings surprise of 12.4% [11][12]

Core Insights - Zacks Premium provides various tools for investors to enhance their stock market engagement and confidence [1][2] Zacks Style Scores - Zacks Style Scores rate stocks based on value, growth, and momentum, serving as complementary indicators to the Zacks Rank [3] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] Value Score - The Value Score focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [4] Growth Score - The Growth Score assesses a company's future prospects through projected earnings, sales, and cash flow [5] Momentum Score - The Momentum Score identifies stocks with favorable price trends using recent price changes and earnings estimate revisions [6] VGM Score - The VGM Score combines all three Style Scores, highlighting stocks with attractive value, growth, and momentum characteristics [7] Zacks Rank - The Zacks Rank is a proprietary model based on earnings estimate revisions, with 1 (Strong Buy) stocks achieving an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [8][9] - Investors are encouraged to focus on stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal returns [10] Stock to Watch: United Therapeutics (UTHR) - United Therapeutics Corporation specializes in treatments for pulmonary arterial hypertension (PAH) with four marketed medicines [12] - UTHR holds a Zacks Rank of 3 (Hold) and a VGM Score of A, with a Value Style Score of B, supported by a forward P/E ratio of 11.37 [13] - Recent upward revisions in earnings estimates have increased the Zacks Consensus Estimate to $24.20 per share, with an average earnings surprise of 12.4% [13][14]

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

The biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments while offering investors the possibility of significant returns. However, investing in these companies requires a nuanced understanding of their pipelines, regulatory landscapes and market dynamics. Identifying biotech stocks to double your money is certainly no easy feat. But looking at companies with late-stage drug approval potential and market dominance in their respective fields is a great start. While b ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth S ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are th ...

United Therapeutics‘ (UTHR) first-quarter 2024 earnings of $6.17 per share beat the Zacks Consensus Estimate of $5.63. Earnings rose 27% year over year on the back of higher product sales.Revenues were $677.7 million, which beat the Zacks Consensus Estimate of $628 million. Revenues rose 34% year over year, driven by meaningful growth of all key products — Tyvaso, Orenitram, Remodulin and Unituxin.Quarter in DetailUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Remoduli ...

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Executive Vice President-Product Development and Xenotransplantation Conference Call Participants Terence Flynn - Morgan Stanley Roanna Ruiz - Leerink Ash ...